{"entity":{"type":"insider","cik":"0001628048","url":"/insider/0001628048","json_url":"/insider/0001628048.json","name":"Vivo Capital Surplus Fund VIII, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":85,"n_filings":20,"first":"2018-01-29","last":"2024-04-03","span_basis":"filed_date"},"name_variants":[{"name":"Vivo Capital Surplus Fund VIII, L.P.","source":"filing","n_filings":20,"first_seen":"2018-01-29","last_seen":"2024-04-03"}],"transactions":[{"id":2093075,"accession":"0001213900-24-030020","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001213900-24-030020","line_url":"/filing/0001213900-24-030020","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":138066.0,"shares_display":"138,066","price_per_share":6.2,"price_display":"6.20","price_state":"stated","total_value":856009.2,"total_display":"856,009.20","total_whole":"856,009","shares_owned_after":4023741.0,"shares_owned_after_display":"4,023,741","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-03","filed_date":"2024-04-03","scope":"insider","n_lines":3},{"id":2093069,"accession":"0001213900-24-030020","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-24-030020","line_url":"/filing/0001213900-24-030020","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":101480.0,"shares_display":"101,480","price_per_share":6.65,"price_display":"6.65","price_state":"stated","total_value":674842.0,"total_display":"674,842.00","total_whole":"674,842","shares_owned_after":4127611.0,"shares_owned_after_display":"4,127,611","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-02","filed_date":"2024-04-03","scope":"insider","n_lines":3},{"id":2093063,"accession":"0001213900-24-030020","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-24-030020","line_url":"/filing/0001213900-24-030020","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":181117.0,"shares_display":"181,117","price_per_share":6.99,"price_display":"6.99","price_state":"stated","total_value":1266007.83,"total_display":"1,266,007.83","total_whole":"1,266,008","shares_owned_after":4203957.0,"shares_owned_after_display":"4,203,957","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-04-01","filed_date":"2024-04-03","scope":"insider","n_lines":3},{"id":8754569,"accession":"0001213900-23-097043","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-23-097043","line_url":"/filing/0001213900-23-097043","is_derivative":false,"issuer_cik":"0001445499","issuer_name":"IMPEL PHARMACEUTICALS INC","issuer_ticker":"IMPL","issuer_name_source":null,"issuer_url":"/issuer/0001445499","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":237289.0,"shares_display":"237,289","price_per_share":0.08,"price_display":"0.08","price_state":"stated","total_value":18983.12,"total_display":"18,983.12","total_whole":"18,983","shares_owned_after":2029495.0,"shares_owned_after_display":"2,029,495","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-19","filed_date":"2023-12-19","scope":"insider","n_lines":2},{"id":8754558,"accession":"0001213900-23-097043","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-23-097043","line_url":"/filing/0001213900-23-097043","is_derivative":false,"issuer_cik":"0001445499","issuer_name":"IMPEL PHARMACEUTICALS INC","issuer_ticker":"IMPL","issuer_name_source":null,"issuer_url":"/issuer/0001445499","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":237711.0,"shares_display":"237,711","price_per_share":0.11,"price_display":"0.11","price_state":"stated","total_value":26148.21,"total_display":"26,148.21","total_whole":"26,148","shares_owned_after":2238152.0,"shares_owned_after_display":"2,238,152","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-18","filed_date":"2023-12-19","scope":"insider","n_lines":2},{"id":8754551,"accession":"0001213900-23-097043","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-23-097043","line_url":"/filing/0001213900-23-097043","is_derivative":false,"issuer_cik":"0001445499","issuer_name":"IMPEL PHARMACEUTICALS INC","issuer_ticker":"IMPL","issuer_name_source":null,"issuer_url":"/issuer/0001445499","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":0.29,"price_display":"0.29","price_state":"stated","total_value":29000.0,"total_display":"29,000.00","total_whole":"29,000","shares_owned_after":2447181.0,"shares_owned_after_display":"2,447,181","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-12-15","filed_date":"2023-12-19","scope":"insider","n_lines":2},{"id":8024134,"accession":"0001213900-23-089692","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-23-089692","line_url":"/filing/0001213900-23-089692","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Panda Fund, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Panda, LLC; Vivo Opportunity, LLC; Vivo Capital VIII, LLC","owner_display_name":"Vivo Panda Fund, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3400.0,"shares_display":"3,400","price_per_share":0.9,"price_display":"0.90","price_state":"stated","total_value":3060.0,"total_display":"3,060.00","total_whole":"3,060","shares_owned_after":1952302.0,"shares_owned_after_display":"1,952,302","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-21","filed_date":"2023-11-22","scope":"insider","n_lines":3},{"id":8727901,"accession":"0001213900-23-088909","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001213900-23-088909","line_url":"/filing/0001213900-23-088909","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.; Vivo Panda, LLC; Vivo Opportunity, LLC; Vivo Panda Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54700.0,"shares_display":"54,700","price_per_share":0.92,"price_display":"0.92","price_state":"stated","total_value":50324.0,"total_display":"50,324.00","total_whole":"50,324","shares_owned_after":1954009.0,"shares_owned_after_display":"1,954,009","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-20","filed_date":"2023-11-20","scope":"insider","n_lines":3},{"id":8727892,"accession":"0001213900-23-088909","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-23-088909","line_url":"/filing/0001213900-23-088909","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.; Vivo Panda, LLC; Vivo Opportunity, LLC; Vivo Panda Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Comon Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16354.0,"shares_display":"16,354","price_per_share":0.93,"price_display":"0.93","price_state":"stated","total_value":15209.22,"total_display":"15,209.22","total_whole":"15,209","shares_owned_after":1981474.0,"shares_owned_after_display":"1,981,474","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-17","filed_date":"2023-11-20","scope":"insider","n_lines":3},{"id":8727886,"accession":"0001213900-23-088909","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-23-088909","line_url":"/filing/0001213900-23-088909","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.; Vivo Panda, LLC; Vivo Opportunity, LLC; Vivo Panda Fund, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":15000.0,"shares_display":"15,000","price_per_share":0.96,"price_display":"0.96","price_state":"stated","total_value":14400.0,"total_display":"14,400.00","total_whole":"14,400","shares_owned_after":1989685.0,"shares_owned_after_display":"1,989,685","ownership_form":"I","is_10b5_1":null,"transaction_date":"2023-11-16","filed_date":"2023-11-20","scope":"insider","n_lines":3},{"id":6789660,"accession":"0001213900-22-082664","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-082664","line_url":"/filing/0001213900-22-082664#line-1","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.; Vivo Opportunity, LLC","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":758620.0,"shares_display":"758,620","price_per_share":7.25,"price_display":"7.25","price_state":"stated","total_value":5499995.0,"total_display":"5,499,995.00","total_whole":"5,499,995","shares_owned_after":4340212.0,"shares_owned_after_display":"4,340,212","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-12-23","filed_date":"2022-12-23","scope":"insider"},{"id":6193788,"accession":"0001213900-22-054888","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-054888","line_url":"/filing/0001213900-22-054888#line-1","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund Holdings, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":600000.0,"shares_display":"600,000","price_per_share":3.6,"price_display":"3.60","price_state":"stated","total_value":2160000.0,"total_display":"2,160,000.00","total_whole":"2,160,000","shares_owned_after":3581592.0,"shares_owned_after_display":"3,581,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-09-07","filed_date":"2022-09-08","scope":"insider"},{"id":6336932,"accession":"0001213900-22-048763","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-22-048763","line_url":"/filing/0001213900-22-048763#line-3","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Capital VIII, LLC; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1500000.0,"shares_display":"1,500,000","price_per_share":2.42,"price_display":"2.42","price_state":"stated","total_value":3630000.0,"total_display":"3,630,000.00","total_whole":"3,630,000","shares_owned_after":2981592.0,"shares_owned_after_display":"2,981,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-16","filed_date":"2022-08-16","scope":"insider"},{"id":6336929,"accession":"0001213900-22-048763","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-22-048763","line_url":"/filing/0001213900-22-048763#line-2","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Capital VIII, LLC; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1218.0,"shares_display":"1,218","price_per_share":2.99,"price_display":"2.99","price_state":"stated","total_value":3641.82,"total_display":"3,641.82","total_whole":"3,642","shares_owned_after":1481592.0,"shares_owned_after_display":"1,481,592","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-15","filed_date":"2022-08-16","scope":"insider"},{"id":6336926,"accession":"0001213900-22-048763","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-048763","line_url":"/filing/0001213900-22-048763#line-1","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Opportunity Fund Holdings, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Capital VIII, LLC; Vivo Opportunity, LLC","owner_display_name":"Vivo Opportunity Fund Holdings, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1123021.0,"shares_display":"1,123,021","price_per_share":2.98,"price_display":"2.98","price_state":"stated","total_value":3346602.58,"total_display":"3,346,602.58","total_whole":"3,346,603","shares_owned_after":1480374.0,"shares_owned_after_display":"1,480,374","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-08-12","filed_date":"2022-08-16","scope":"insider"},{"id":4541764,"accession":"0001213900-21-023652","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0001213900-21-023652","line_url":"/filing/0001213900-21-023652","is_derivative":false,"issuer_cik":"0001445499","issuer_name":"IMPEL NEUROPHARMA INC","issuer_ticker":"IMPL","issuer_name_source":null,"issuer_url":"/issuer/0001445499","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.; Vivo Capital Surplus Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":575000.0,"shares_display":"575,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":8625000.0,"total_display":"8,625,000.00","total_whole":"8,625,000","shares_owned_after":2535115.0,"shares_owned_after_display":"2,535,115","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-04-27","filed_date":"2021-04-29","scope":"insider","n_lines":2},{"id":5107551,"accession":"0001567619-21-002591","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001567619-21-002591","line_url":"/filing/0001567619-21-002591","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.; Vivo Capital VIII, LLC","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":475000.0,"shares_display":"475,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":8075000.0,"total_display":"8,075,000.00","total_whole":"8,075,000","shares_owned_after":357353.0,"shares_owned_after_display":"357,353","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":4924723,"accession":"0001209191-21-008758","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001209191-21-008758","line_url":"/filing/0001209191-21-008758","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Panda, LLC; Vivo Opportunity Fund, L.P.; Vivo Panda Fund, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity, LLC; Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Panda, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":226.0,"shares_display":"226","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":4520.0,"total_display":"4,520.00","total_whole":"4,520","shares_owned_after":1821483.0,"shares_owned_after_display":"1,821,483","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":4924713,"accession":"0001209191-21-008758","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-21-008758","line_url":"/filing/0001209191-21-008758","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Panda, LLC; Vivo Opportunity Fund, L.P.; Vivo Panda Fund, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity, LLC; Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Panda, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":350000.0,"shares_display":"350,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":7000000.0,"total_display":"7,000,000.00","total_whole":"7,000,000","shares_owned_after":1997216.0,"shares_owned_after_display":"1,997,216","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":2318480,"accession":"0001567619-20-018010","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001567619-20-018010","line_url":"/filing/0001567619-20-018010","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Aligos Therapeutics, Inc.","issuer_ticker":"ALGS","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.; Vivo Capital Surplus Fund VIII, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":550000.0,"shares_display":"550,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":8250000.0,"total_display":"8,250,000.00","total_whole":"8,250,000","shares_owned_after":3116658.0,"shares_owned_after_display":"3,116,658","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-10-20","filed_date":"2020-10-20","scope":"insider","n_lines":2},{"id":2598434,"accession":"0001213900-20-009500","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-20-009500","line_url":"/filing/0001213900-20-009500","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Fund VIII, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital VIII, LLC","owner_display_name":"Vivo Capital Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":84598.0,"shares_display":"84,598","price_per_share":15.4,"price_display":"15.40","price_state":"stated","total_value":1302809.2,"total_display":"1,302,809.20","total_whole":"1,302,809","shares_owned_after":2162587.0,"shares_owned_after_display":"2,162,587","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-04-17","filed_date":"2020-04-17","scope":"insider","n_lines":2},{"id":2598424,"accession":"0001213900-20-009500","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001213900-20-009500","line_url":"/filing/0001213900-20-009500","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Fund VIII, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital VIII, LLC","owner_display_name":"Vivo Capital Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":30190.0,"shares_display":"30,190","price_per_share":15.2,"price_display":"15.20","price_state":"stated","total_value":458888.0,"total_display":"458,888.00","total_whole":"458,888","shares_owned_after":2236920.0,"shares_owned_after_display":"2,236,920","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-04-16","filed_date":"2020-04-17","scope":"insider","n_lines":2},{"id":2598416,"accession":"0001213900-20-009500","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001213900-20-009500","line_url":"/filing/0001213900-20-009500#line-2","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Fund VIII, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital VIII, LLC","owner_display_name":"Vivo Capital Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":3,"other_reporting_owners":2,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":189625.0,"shares_display":"189,625","price_per_share":15.5,"price_display":"15.50","price_state":"stated","total_value":2939187.5,"total_display":"2,939,187.50","total_whole":"2,939,188","shares_owned_after":2263447.0,"shares_owned_after_display":"2,263,447","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-04-15","filed_date":"2020-04-17","scope":"insider"}],"collapsed":true,"next_cursor":"2020-04-15|2598416","ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001831363","name":"Terns Pharmaceuticals, Inc.","url":"/issuer/0001831363","role":"Ten percent owner","n_filings":5,"first_seen":"2021-02-09","last_seen":"2024-04-03"},{"type":"issuer","type_label":"ISSUER","cik":"0001445499","name":"IMPEL PHARMACEUTICALS INC","url":"/issuer/0001445499","role":"Ten percent owner","n_filings":2,"first_seen":"2021-04-29","last_seen":"2023-12-19"},{"type":"issuer","type_label":"ISSUER","cik":"0001641281","name":"Bolt Biotherapeutics, Inc.","url":"/issuer/0001641281","role":"Ten percent owner","n_filings":3,"first_seen":"2021-02-09","last_seen":"2023-11-22"},{"type":"issuer","type_label":"ISSUER","cik":"0001799448","name":"Aligos Therapeutics, Inc.","url":"/issuer/0001799448","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-20","last_seen":"2020-10-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001658247","name":"Crinetics Pharmaceuticals, Inc.","url":"/issuer/0001658247","role":"Ten percent owner","n_filings":8,"first_seen":"2018-07-20","last_seen":"2020-04-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001566044","name":"Menlo Therapeutics, Inc.","url":"/issuer/0001566044","role":"Ten percent owner","n_filings":1,"first_seen":"2018-01-29","last_seen":"2018-01-29"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001628048","retrieved_at":"2026-08-23T02:22:51+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}